Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04565327 · ClinicalTrials.gov registry record · Phase 2
Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
A Phase 2 study, sponsored by Zhen Wang, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04565327: Clinical Trial Phase 2 study, sponsored by Zhen Wang, MD.
NCT04565327 is a Phase 2 study that was terminated before completion, run by Zhen Wang, MD. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04565327, a Phase 2 study, was terminated before completion, sponsored by Zhen Wang, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase II trial investigates whether magnetic resonance imaging (MRI) using hyperpolarized carbon-13 (13C) pyruvate can be useful for evaluating early treatment response in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or spread to other places in the body (metastatic). Hyperpolarized 13C pyruvate is different from standard clinical MRI contrast (e.g. gadolinium) in that it provides information on how a tumor processes nutrients. MRI is used to see tumor uptake and breakdown of hyperpolarized carbon-13 pyruvate molecules, which can tell how the tumor processes nutrients. Hyperpolarized 13C pyruvate MRI may help in understanding how the tumor responds to the treatments patients may be receiving.
Primary Outcome
Descriptive statistics will be used to summarize the mean, standard deviation, and 95% confidence interval of the measurements.
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- DRUG Hyperpolarized Carbon C 13 Pyruvate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Why NCT04565327 stopped before completion
NCT04565327 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT04565327 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04565327 about?
NCT04565327 is a clinical study titled "Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma". This phase II trial investigates whether magnetic resonance imaging (MRI) using hyperpolarized carbon-13 (13C) pyruvate can be useful for evaluating early treatment response in patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced) or spread to other place...
What is the current status of trial NCT04565327?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2020-08-14. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT04565327?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (DRUG).
Who is sponsoring clinical trial NCT04565327?
This trial is sponsored by Zhen Wang, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04565327's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI